Biofrontera Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Biofrontera has been growing earnings at an average annual rate of 1.7%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 1.5% per year.

Anahtar bilgiler

1.7%

Kazanç büyüme oranı

4.3%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi7.3%
Gelir büyüme oranı-1.5%
Özkaynak getirisi-14.4%
Net Marj-11.8%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Biofrontera AG (ETR:B8FK) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Oct 13
Biofrontera AG (ETR:B8FK) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Biofrontera AG (ETR:B8FK) Not Doing Enough For Some Investors As Its Shares Slump 47%

May 21
Biofrontera AG (ETR:B8FK) Not Doing Enough For Some Investors As Its Shares Slump 47%

Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price Plunge

Mar 07
Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price Plunge

We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate

Feb 19
We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate

Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This Year

Dec 07
Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This Year

Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?

Jun 08
Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?

Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 14
Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Gelir ve Gider Dağılımı

Biofrontera nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

XTRA:B8FK Gelir, gider ve kazançlar (EUR Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 2422-3118
31 Mar 24300128
31 Dec 23320138
30 Sep 2329-9138
30 Jun 2328-11138
31 Mar 2325-20137
31 Dec 2226-44127
30 Sep 223211187
30 Jun 223110247
31 Mar 223015297
31 Dec 212938347
30 Sep 2128-16286
30 Jun 2127-16295
31 Mar 2129-12265
31 Dec 2030-13285
30 Sep 2033-17335
30 Jun 2033-22375
31 Mar 2031-10455
31 Dec 1931-7445
30 Sep 19261444
30 Jun 19268405
31 Mar 1923-8335
31 Dec 1821-9314
30 Sep 1819-14244
30 Jun 1816-15224
31 Mar 1814-16214
31 Dec 1712-16204
30 Sep 1711-18215
30 Jun 179-16175
31 Mar 178-14145
31 Dec 166-11125
30 Sep 164-994
30 Jun 164-784
31 Mar 164-976
31 Dec 154-1176
30 Sep 154-1277
30 Jun 153-1377
31 Mar 153-1075
31 Dec 143-1175
30 Sep 143-1074
30 Jun 143-1074
31 Mar 143-964
31 Dec 133-853

Kaliteli Kazançlar: B8FK is currently unprofitable.

Büyüyen Kar Marjı: B8FK is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: B8FK is unprofitable, but has reduced losses over the past 5 years at a rate of 1.7% per year.

Büyüme Hızlandırma: Unable to compare B8FK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: B8FK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).


Özkaynak Getirisi

Yüksek ROE: B8FK has a negative Return on Equity (-14.38%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin